- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03199131
The Right Ventricle in Chronic Pressure Overload: Identifying Novel Molecular Targets for Functional Imaging (MVD)
21. januar 2020 opdateret af: Centre Chirurgical Marie Lannelongue
Chronically elevated pulmonary pressures do not immediately result in right ventricular failure.
During the initial period of exposure, the RV adapts to the increased afterload by altering its metabolism and morphology so as to meet the increased work requirement.
Several, interconnected adaptive mechanisms have been proposed, including myocyte hypertrophy, a switch in the primary fuel used for ATP generation, increased angiogenesis, and decreased production of mitochondrial reactive oxygen species.
While adaptation is initially successful in many cases, it is temporary, and after an uncertain period of time, the ventricle begins to fail.
This transition from a compensated to decompensated state is difficult to predict clinically, and patients with different etiologies of CPOS progress to overt RV failure over significantly different time periods.
This variability hinders the implementation of treatments that are tailored to a specific disease stage.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Chronically elevated pulmonary pressures do not immediately result in right ventricular failure.
During the initial period of exposure, the RV adapts to the increased afterload by altering its metabolism and morphology so as to meet the increased work requirement.
Several, interconnected adaptive mechanisms have been proposed, including myocyte hypertrophy, a switch in the primary fuel used for ATP generation, increased angiogenesis, and decreased production of mitochondrial reactive oxygen species.
While adaptation is initially successful in many cases, it is temporary, and after an uncertain period of time, the ventricle begins to fail.
This transition from a compensated to decompensated state is difficult to predict clinically, and patients with different etiologies of CPOS progress to overt RV failure over significantly different time periods.
This variability hinders the implementation of treatments that are tailored to a specific disease stage.
As right heart failure is the primary outcome determinant in patients with pulmonary hypertension, understanding the major mediators of RV compensation, failure and recovery is essential to improving patient survival.
Recently, there have been significant advances in the ability to assess RV function in vivo using functional imaging techniques, including positron emission tomography (PET) and cardiac MRI (CMR).
CMR is an established and validated method of precisely defining cardiac structure and function, and new PET protocols have been developed that measure glucose utilization, oxygen consumption, apoptosis and angiogenesis.
Importantly, the in vivo nature of PET and CMR allow for the non-invasive collection of detailed structural, metabolic and physiologic data on the performance of the RV5.
When taken in combination with established echocardiographic evaluation, these new platforms allow in-depth analysis of cardiac structure and function without the need for invasive procedures.
In order to maximize the potential of these techniques, however, a molecular imaging target needs to be identified so as to allow physicians to detect the transition from a compensated to decompensated state.
Such a marker has not yet been reported
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
20
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Le Plessis-Robinson, Frankrig, 92350
- Centre chirurgical Marie Lannelongue
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
-Inclusion Criteria:
Chronic thromboembolic pulmonary hypertension group:
- Patients undergoing pulmonary endarterectomy at Marie Lannelongue Surgical Center for the treatment of chronic thromboembolic pulmonary hypertension.
Control group:
- Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension on preoperative assessment
- Exclusion Criteria:
Chronic thromboembolic pulmonary hypertension group:
- Insufficient biopsy material,
- pre-operative therapy with bosentan or sildenafil
Control group:
- Insufficient biopsy sample,
- ischemic cardiomyopathy,
- miral or tricuspid valve disease,
- pre-operative pulmonary hypertension.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: CTEPH
Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
|
a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
|
|
Andet: Control group
Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
|
a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
relationship between the metabolic, morphologic and functional alterations in the right ventricle
Tidsramme: to investigate the relationship between the metabolic, morphologic and functional alterations in the right ventricle before surgery,one and six months after surgery.
|
to investigate the relationship between the metabolic, morphologic and functional alterations in the right ventricle before surgery,one and six months after surgery.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
validation in human subjects of metabolic signaling pathway alterations found in animal model
Tidsramme: analyse gene and protein expression during surgery
|
analyse gene and protein expression during surgery
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Olaf Mercier, MD, PhD, Marie Lannelongue Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. februar 2017
Primær færdiggørelse (Faktiske)
20. november 2017
Studieafslutning (Faktiske)
20. oktober 2018
Datoer for studieregistrering
Først indsendt
22. marts 2017
Først indsendt, der opfyldte QC-kriterier
23. juni 2017
Først opslået (Faktiske)
26. juni 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
23. januar 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. januar 2020
Sidst verificeret
1. januar 2020
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2015-A00149-40
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Right ventricular biopsies
-
Western Michigan UniversityBlue Cross Blue Shield of Michigan FoundationAfsluttet
-
Abbott Medical DevicesThoratec CorporationAfsluttetCentriMag ventrikulært hjælpesystem til behandling af manglende fravænning fra kardiopulmonal bypassHjertefejlForenede Stater
-
Abbott Medical DevicesThoratec CorporationTrukket tilbage
-
Versailles HospitalCentre Hospitalier Sud FrancilienAktiv, ikke rekrutterende
-
Abbott Medical DevicesThoratec Corporation; KCRI; Center for Life Sciences; EmergoAfsluttetAvanceret refraktær venstre ventrikulær hjertesvigtTyskland, Australien, Østrig, Canada, Tjekkiet, Kasakhstan
-
Medtronic Cardiac Rhythm and Heart FailureAfsluttet
-
University Hospitals, LeicesterAfsluttet
-
Shenzhen Core Medical Technology CO.,LTD.Rekruttering
-
Shenzhen Core Medical Technology CO.,LTD.Rekruttering
-
Medical Research Council, South AfricaAga Khan University; Texas Woman's UniversityUkendt